Saving up to 80% on Hepatitis C medication
28 julio 2017

The Colombian Ministry of Health announced the country’s participation in the Pan American Health Organization (PAHO)’s a new centralized acquisition system which provides cheaper access to medication. The system will save the Colombian government 292,000 colombian pesos (U$S98.806.000) in its first year while improving access to medication for hepatitis C patients.

Negotiations with PAHO included two treatments for Hepatitis C: Harvoni (Ledipasvir/sofosbuvir), the cost of which reduce from $114.3 to $23.5 million Colombian pesos; and Daklinza (daclatasvir) and Sovaldi (sofosbuvir), with costs going from $137.2 to $29 million per patient.

According to Minister Alejandro Gaviria, 400,000 Colombians carry the Hepatitis C virus, 60,000 of which will require treatment between 2017 and 2030. State investment to treat Hepatitis C patients for the next 14 years will be much lower at 7.8 billion Colombian pesos (around U$S2,586 million).

Noticias Relacionadas